"...patient presenting with severe preeclampsia/HELLP syndrome at 26 weeks gestation that was treated with Eculizumab, a targeted inhibitor of complement protein C5, which resulted in marked clinical improvement and complete normalization of lab parameters. Pregnancy was prolonged 17 days, likely resulting in a reduction of neonatal morbidity with its associated short and long-term health care costs. Successful use of Eculizumab in this case suggests that complement inhi- bition may be an effective treatment strategy for severe preeclampsia/HELLP syndrome."
article in press as: Burwick RM, Feinberg BB, Eculizumab for the treatment of preeclampsia/HELLP syndrome, Placenta (2012), http://dx.doi.org/10.1016/j.placenta.2012.11.014
